For most people, Neurontin (Gabapentin) will work for chronic back pain.

Neurontin is not excreted through the liver like most things, by excreted through the kidneys. It has been used for treatment of partial seizures in patients from the ages 3-12.

Neurontin was originally approved for sale in the mid 1990’s as a treatment for epileptic seizures. The FDA has approved this to treat epilepsy when it is used with another drug for pain related shingles. Neurontin is usually taken in 3 equal doses each day.

Gabapentin is indicated for the management of postherpetic neuralgia in adults. This medicine does not interact with other seizure medicines, so it can be used as an add on. It has not been approved to treat severe RLS (restless leg syndrome).

Neurontin is expensive and one of the best selling drug in the world used for the treatment of chronic back pain. The average cost is $400/month for 3200mg/day. The effects are good even though it is an expensive drug to treat pain.

Neurontin is the first oral medication approved by the FDA and found in breast milk. It was prescribed for epilepsy. The medicine has also been approved for a few off label uses. One of the biggest selling points is that it has few side effects.

Neurontin is not metabolized by the body. It does not produce any active or inactive metabolites. You can take it orally with or without food. Neurontin is not for pain management. For chronic back pain, it is good for the nerve damage.

The manufacturer of Neurontin is Pfizer. It is so popular it is one of the 50 most prescribed drugs in the United States since 2003.

Neurontin is usually tried first because it is often better tolerated than other drugs. It has realatively mild side effects and passes through the body unmetabolized.

If you're new here, you may want to subscribe to my RSS feed. Thanks for visiting!

(No Ratings Yet)

 Loading ...

 |  Email This Post  |  Print This Post  |  Subscribe to It!
This entry was posted on Sunday, July 6th, 2008 at 2:43 am and is filed under Exercise. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.